These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22180403)

  • 21. CA125 and HE4: Measurement Tools for Ovarian Cancer.
    Zhao T; Hu W
    Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human epididymal protein 4 (HE4) is a novel biomarker and a promising prognostic factor in ovarian cancer patients.
    Chudecka-Głaz A; Rzepka-Górska I; Wojciechowska I
    Eur J Gynaecol Oncol; 2012; 33(4):382-90. PubMed ID: 23091895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The diagnostic accuracy of human epididymis protein 4 (HE4) for discriminating between benign and malignant pelvic masses: a systematic review and meta-analysis.
    Olsen M; Lof P; Stiekema A; van den Broek D; Wilthagen EA; Bossuyt PM; Lok CAR
    Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1788-1799. PubMed ID: 34212386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.
    Li F; Tie R; Chang K; Wang F; Deng S; Lu W; Yu L; Chen M
    BMC Cancer; 2012 Jun; 12():258. PubMed ID: 22712526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
    Dewan R; Dewan A; Jindal M; Bhardawaj M
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
    Zhang L; Chen Y; Wang K
    Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer.
    Dikmen ZG; Colak A; Dogan P; Tuncer S; Akbiyik F
    Eur J Gynaecol Oncol; 2015; 36(4):457-62. PubMed ID: 26390703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Usefulness of the HE4 biomarker as a second-line test in the assessment of suspicious ovarian tumors.
    Moszynski R; Szubert S; Szpurek D; Michalak S; Krygowska J; Sajdak S
    Arch Gynecol Obstet; 2013 Dec; 288(6):1377-83. PubMed ID: 23722285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4.
    Han KH; Park NH; Kim JJ; Kim S; Kim HS; Lee M; Song YS
    J Gynecol Oncol; 2019 Nov; 30(6):e83. PubMed ID: 31576682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis.
    Gąsiorowska E; Michalak M; Warchoł W; Lemańska A; Jasiński P; Spaczyński M; Nowak-Markwitz E
    Ginekol Pol; 2015 Feb; 86(2):88-93. PubMed ID: 25807831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive serum glycopeptide spectra analysis to identify early-stage epithelial ovarian cancer.
    Mikami M; Tanabe K; Imanishi T; Ikeda M; Hirasawa T; Yasaka M; Machida H; Yoshida H; Hasegawa M; Shimada M; Kato T; Kitamura S; Kato H; Fujii T; Kobayashi Y; Suzuki N; Tanaka K; Murakami I; Katahira T; Hayashi C; Matsuo K
    Sci Rep; 2024 Aug; 14(1):20000. PubMed ID: 39198565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
    Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Diagnostic value of CA125, HE4 and Copenhagen Index in differentiating benign from malignant epithelial ovarian tumors].
    Gong SP; Chen YN; Zhang YD; Yao W; Chen L; Liu SS; Wu H
    Nan Fang Yi Ke Da Xue Xue Bao; 2017 May; 37(5):628-632. PubMed ID: 28539285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HE4 as an Early Detection Biomarker of Epithelial Ovarian Cancer: Investigations in Prediagnostic Specimens From the Janus Serumbank.
    Gislefoss RE; Langseth H; Bolstad N; Nustad K; Mørkrid L
    Int J Gynecol Cancer; 2015 Nov; 25(9):1608-15. PubMed ID: 26501436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status: use in differentiation of ovarian cancers and benign lesions.
    Macuks R; Baidekalna I; Donina S
    Tumour Biol; 2012 Oct; 33(5):1811-7. PubMed ID: 22696162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
    Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
    Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women.
    Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
    Tumour Biol; 2016 Feb; 37(2):2183-91. PubMed ID: 26349751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer.
    Kim B; Park Y; Kim B; Ahn HJ; Lee KA; Chung JE; Han SW
    J Clin Lab Anal; 2019 Jan; 33(1):e22624. PubMed ID: 30009497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.